Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 269,917

Document Document Title
WO/2021/092588A1
Disclosed herein are methods for modulating hair growth and increasing hair follicle stem cell activation in an individual in need thereof. This includes administering an agent that modulates a Gas6-Tyro3-Axl-Mertk (TAM) interaction or p...  
WO/2021/092360A1
The present application is directed to reducing virus levels and treating virus infection in a subject. This treatment achieved by targeting cellular host factors in the subject, these being GRP78/BIP, SRSF1, HNRNP A2B 1, RPLP1 and RPLP2...  
WO/2021/092073A1
The disclosure relates generally to methods of modifying a nucleic acid sequence, systems for modifying a nucleic acid sequence, and compositions made by said methods or systems.  
WO/2021/062124A3
Described herein are methods and compositions for the prevention or treatment of obesity and obesity-related disorders. The methods and compositions are based, inter alia, on the observations that OPN3 is the most highly expressed opsin ...  
WO/2021/092459A1
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of SPDEF RNA in a cell or subject, and in certain instances reducing the amount of SPDEF protein in a cell or subject. These compounds, ...  
WO/2021/041932A3
Provided herein, inter alia, are genetically engineered microbes and methods of use thereof for producing L-4-chlorokynrenine from L-Tryptophan. The genetically engineered microbes include, inter alia, one or more exogenous nucleic acids...  
WO/2021/092145A1
The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR- associated ocular diseases.  
WO/2021/091927A1
Disclosed herein include systems, methods, and compositions for determining perturbations in single cells or performing integrated measurements using, for example, plasmids each comprising (i) a perturbation gRNA with a guide region targ...  
WO/2021/092300A1
The technology described herein provides variant adeno-associated viral capsid polypeptides and viruses comprising the same. Further provided herein are methods for delivering a viral payload using viruses comprising variant capsid polyp...  
WO/2021/089828A1
Provided is a compound for use in preventing, treating or delaying progression of a disease involving aberrant fibroblast proliferation. The compound is a compound effective in reducing the level of 5 tyrosine phosphatase activity effect...  
WO/2021/088317A1
Provided are an miRNA marker for the diagnosis and/or treatment of Alzheimer's disease. The miRNA marker is an miRNA-23 cluster. Also provided are the use of the microRNA of the miRNA-23 cluster in the diagnosis and/or treatment of Alzhe...  
WO/2021/088825A1
Provided are an F-genotype mumps virus attenuated strain, a construction method therefor and an application thereof. The attenuated strain is a mumps virus QS-F-SH2 with the accession number of CCTCC NO: V201950. Further provided are a v...  
WO/2021/092472A1
Disclosed are methods and compositions which can be used to treat diseases or disorders associated with an elevated amount of oxalate, including, for example, hyperoxaluria, in particular enteric hyperoxaluria.  
WO/2021/067664A3
Described herein are compositions, kits and methods for shredding the genomes of selected cell types, for example, the genomes of selected cancer cell types.  
WO/2021/088601A1
Provided is a method for creating fixed point mutations in organisms without an artificial DNA template, and an application thereof. The method comprises the following steps: at a specific position in the genome of an organism, two or mo...  
WO/2021/092226A1
Described herein, in certain embodiments, are methods of determining an outcome of at least one embryo following transfer of the embryo to a recipient female, where the outcome is based on the expression of at least one gene in an endome...  
WO/2021/092392A1
The present application relates to method of vaccinating a subject against infection by an enveloped virus. The method includes providing a compound of the Formula (I) as described herein, and contacting the compound of Formula (I) with ...  
WO/2021/088923A1
Disclosed are a method for creating a new gene in an organism without an artificial DNA template and the use thereof. The method comprises simultaneously generating DNA breakages in at least two different specific positions in the genome...  
WO/2021/087894A1
Disclosed are a ketoreductase mutant and a method for producing a chiral alcohol. The ketoreductase mutant has a sequence with amino acid mutations in the sequence shown in SEQ ID NO:1. The mutation sites comprise K200H. In the present i...  
WO/2021/092210A1
Disclosed here are phage compositions comprising CRISPR-Cas systems and methods of use thereof. In certain embodiments, disclosed herein is a bacteriophage comprising a nucleic acid sequence encoding a Type I CRISPR-Cas system comprising...  
WO/2021/091935A1
The present invention provides methods for producing allogeneic T-cells, including the use of an engineered nuclease under the control of a controllable promoter. By preparing T-cells with an inducible nuclease, large volumes of cells ca...  
WO/2021/087586A1
The present invention relates to a novel transgenic corn event expressing a truncated or modified form of the insecticidal protein Cry1Da designated event ME240913. The invention relates to the unique nucleic acids for the event ME240913...  
WO/2021/090877A1
This brain organoid, which has a phosphorylated 3-repeat tau protein and a phosphorylated 4-repeat tau protein, can be produced by a brain organoid production method including a step 1 for performing floating culture on human pluripotent...  
WO/2021/092236A1
Methods and systems for deconvoluting tumor ecosystems for personalized cancer therapy are disclosed. Generally, human cancers exhibit large variation in behavior between and within patients, which is in large part related to cellular co...  
WO/2021/089736A1
The present invention relates to the treatment of muscular diseases.  
WO/2021/091940A1
The disclosure provides polynucleotides containing inner hair cell-specific promoters, as well as vectors containing the same, that can be used to promote expression of a transgene specifically in inner hair cells. The polynucleotides de...  
WO/2021/092589A1
The disclosed subject matter provides for genetically modified cells, e.g, fungal cells, that autonomously generates and/or secretes one or more therapeutic molecules, e.g, therapeutic peptides, therapeutic proteins or small therapeutic ...  
WO/2021/092386A1
Disclosed herein include systems, methods, compositions, and kits for labeling nucleic acid targets in a sample. In some embodiments, nucleic acid targets (e.g., mRNAs) are initially barcoded on the 3' end and are subsequently barcoded o...  
WO/2021/090925A1
Provided are a polypeptide having excellent 4-aminobenzoic acid hydroxylation activity and a method for using the polypeptide. This polypeptide having 4-aminobenzoic acid hydroxylation activity comprises an amino acid sequence represen...  
WO/2021/092140A1
A method of enriching Veillonellaand reducing lactate in the gut microbiome in a subject, comprising administering to the subject a therapeutically effective amount of a chimeric peptide sequence, thereby enriching Veillonella and reduci...  
WO/2021/071788A3
Among other things, the present disclosure provides C9orf72 oligonucleotides, compositions, and methods thereof. In some embodiments, the present disclosure provides methods for treating C9orf72-associated conditions, disorders or diseas...  
WO/2021/088370A1
Provided is a fungal operon, an exogeneous gene site-directed quantitative fixed-time expression system based on the fungal operon, and applications of the system in expressing heterogeneous genes. The system comprises the following sequ...  
WO/2021/092581A1
Provided herein are genetically engineered mammalian stem and progenitor cells that have increased potential to differentiate into regulatory T cells. Also provided are methods of making and use thereof.  
WO/2021/092227A1
Methods for inactivating in a cell a mutant allele of the elastase, neutrophil expressed gene (ELANE gene) gene having a mutation associated with severe congenital neutropenia (SCN) or cyclic neutropenia (CyN) and which cell is heterozyg...  
WO/2021/092518A1
The present disclosure provides methods and compositions for the treatment of diseases and genetic disorders linked to SLC6A1 loss and/or misfunction. The methods and compositions of the present disclosure comprise rAAV vectors and rAAV ...  
WO/2021/092358A1
The present inventive concept is related to a modified follicle-stimulating hormone (FSH), in particular, a hypo-glycosylated form of FSH, as well as compositions and formulations including, nucleic acids encoding, cell lines expressing,...  
WO/2021/091938A1
The disclosure provides polynucleotides containing outer hair cell-specific promoters, as well as vectors containing the same, that can be used to promote expression of a transgene specifically in outer hair cells. The polynucleotides de...  
WO/2021/092204A1
Methods and compositions related to a nucleic acid-guided nuclease cell targeting screen are provided. The invention relates to compositions and methods for identifying cell targeting proteins that, when associated with a nucleic acid-gu...  
WO/2021/092456A1
Provided herein are method of analyzing genomic and metabolomic data from fungi to identify relationships between biosynthetic gene clusters and mass spectrometric features of metabolites.  
WO/2021/092519A1
The present disclosure provides systems that include a CRISPR-associated (Cas) enzyme with trans cleavage activity; a guide CRISPR RNA (crRNA) including a guide sequence and a polynucleotide extension sequence, wherein the guide sequence...  
WO/2021/088189A1
Disclosed is a method for homogenizing concentrations of different oligonucleotides in an oligonucleotide library and amplifying the oligonucleotide library at room temperature. The method can be used for DNA data storage. The method can...  
WO/2021/089055A1
Provided in the present invention are a Zika/dengue vaccine and an application thereof. The present invention introduces a mutation into the E-protein FL fusion region of the Zika virus or dengue virus, antigens with said mutation being ...  
WO/2021/092356A1
The present disclosure is generally related to modified filamentous fungal strains (cells) comprising enhanced protein productivity phenotypes, wherein such modified strains are particularly well-suited for growth in submerged cultures (...  
WO/2021/092587A1
Provided herein are methods to increase the culture density and/or thickness of a cellular biomass in a cultivation infrastructure, and to promote anchorage-independent growth of a cellular biomass in a cultivation infrastructure. The me...  
WO/2021/092162A1
The present invention provides a recombinant cell for producing para-nitro-L-phenylalanine (pN-Phe). The recombinant cell comprises heterologous genes encoding heterologous enzymes. The recombinant cell expresses the heterologous enzymes...  
WO/2021/092298A1
The technology described herein provides variant adeno-associated viral capsid polypeptides and viruses comprising the same. Further provided herein are methods for delivering a viral payload using viruses comprising variant capsid polyp...  
WO/2021/072146A3
The present invention provides for a method for producing hydrogen peroxide comprising: (a) contacting a methanol with methanol oxidase bound with a flavin adenine dinucleotide (FAD) cofactor, such that the methanol is oxidized into a fo...  
WO/2021/092064A1
The invention relates generally to uses of tRNA-based effector molecules (TREMs) corresponding to con-rare codons and methods of making the same.  
WO/2021/092245A1
This invention generally relates to compositions comprising thaumatin-like proteins (TLP) and chitinases for use as laboratory reagents or biofungicides. The invention further relates to methods of detecting and inducing pathogen resista...  
WO/2018/098117A8
The invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated d...  

Matches 1 - 50 out of 269,917